Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tai Li Sheng Wu Yi Yao
Shanghai, Shanghai, Chinatailibio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Taili Bio is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on the discovery and development of innovative small molecule drugs for oncology and immunology. The company leverages its proprietary drug discovery platform to target high-value pathways such as CDK9 and BTK, aiming to address unmet medical needs in hematological malignancies and solid tumors. Taili Bio's lead programs include TL-010, a highly selective CDK9 inhibitor, and TL-011, a next-generation BTK inhibitor. The company is led by a team of industry veterans with extensive experience in global drug development and has secured significant venture capital funding to advance its pipeline.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Tai Li Sheng Wu Yi Yao.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tai Li Sheng Wu Yi Yao.